Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia

Haematologica. 2018 Dec;103(12):e598-e601. doi: 10.3324/haematol.2017.187070. Epub 2018 Jul 5.

Authors

Silvia Martinelli¹, Rossana Maffei¹, Stefania Fiorcari¹, Chiara Quadrelli¹, Patrizia Zucchini¹, Stefania Benatti¹, Leonardo Potenza¹, Mario Luppi¹, Roberto Marasca²

Affiliations

¹ Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
² Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy roberto.marasca@unimore.it.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology
Cell Movement / drug effects
Cell Movement / genetics
Cell Movement / immunology
Cell Proliferation / drug effects
Cell Proliferation / genetics
Cell Survival / drug effects
Cell Survival / genetics
Cell Survival / immunology
Cells, Cultured
Gene Expression Profiling / methods
Gene Expression Regulation, Leukemic / drug effects
Gene Expression Regulation, Leukemic / immunology
Humans
Immunity, Cellular / drug effects*
Immunity, Cellular / genetics
Immunity, Cellular / immunology
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Purines / pharmacology*
Quinazolinones / pharmacology*
T-Lymphocytes / drug effects*
T-Lymphocytes / immunology
T-Lymphocytes / metabolism

Substances

Antineoplastic Agents
Purines
Quinazolinones
idelalisib